Endonovo Therapeutics Developing Next-Generation Cell

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Endonovo Therapeutics Developing Next-Generation Cell Therapy for Acute and Chronic Graft-Versus-Host Disease Using Cell-Enhancing Cytotronics Platform

LOS ANGELES, CA--(Marketwired - Nov 3, 2015) - Endonovo Therapeutics, Inc. ( OTCQB : ENDV ) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced that it is developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics™ expanded and ex vivo enhanced stem cells from the human umbilical cord.

"We have taken our method of expanding a population of immune privileged stem cells from the human umbilical cord and combined it with our Cytotronics platform to create large quantities of optimized immuno-regulatory stem cells that can be used as an allogeneic, off-the-shelf therapy for the treatment of Graft-Versus-Host Disease," commented Endonovo Chief Scientist, Dr. Donnie Rudd.

Graft-Versus-Host Disease (GVHD) is a common complication following allogeneic tissue transplants, including bone marrow and cord blood transplants, wherein immune cells in the transplanted tissue (the graft) recognize the recipient (the host) as "foreign" and begin to attack the host's cells. Acute GVHD can result in significant damage to the liver, skin, mucosa and the gastrointestinal tract and is a major issue associated with high morbidity and mortality in transplants. The incidence of grade II-IV acute GVHD has been reported to vary between 20-85% in hematopoietic stem cell transplants.

Mesenchymal stem cells (MSCs) are captivating scientists around the world due to their therapeutic nature and ability to be harvested and cultivated quickly. These stem cells are being used to treat a wide variety of inflammatory diseases and have been suggested in the treatment of acute GVHD after bone marrow transplantation due to their ability to modulate the immune response.

Nonetheless, despite the promise of current MSC-based therapies, their poor engraftment and their short-term survival when transplanted are still major limitations to the effective therapeutic use of these stem cells.

"Our Cytotronics platform is particularly suited to address many of the issues that have plagued stem cell therapies that have recently failed, such as their loss of potency and self-renewal when expanded ex vivo , their poor engraftment and their limited ability to survive when transplanted," says Dr. Rudd.

Endonovo previously announced a method and composition process for the creation of a cell mixture from a portion of the human umbilical cord co-cultured with adipose-derived stem cells. The resulting cell mixture provides for a rich source of highly-proliferative, immunosuppressive and non-alloreactive cells that display neither of the major histocompatibility markers (HLA double negative). These immune privileged cells thus represent a significant source of cells for allogeneic mesenchymal cell-based therapies.

Endonovo Therapeutics has used this new technology to create a biologically potent, off-the-shelf, allogeneic treatment for Graft-Versus-Host disease and a wide-array of other conditions.

The Company believes that its development of next-generation cell therapies that have been enhanced ex vivo using its Cytotronics™ platform will be a major innovation in the regenerative medicine market, which is expected to increase from US$2.6 billion in 2012 to US$6.5 billion by 2019, according to Transparency Market Research .

"We are very excited to be a leader in the development of next-generation, ex vivo enhanced cells for regenerative medicine," stated Endonovo CEO, Alan Collier. "We have seen several stem cell therapies fail in clinical trials over the last couple of years, which points to a critical need for the development of methods to increase the biological and therapeutic properties of stem cells."

"We believe that enhancing the biological and therapeutic properties of stem cells using bioelectronics is the future of cell-based therapies," concluded Mr. Collier. 

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and enhancing the biological and therapeutic properties of cells for the development of next-generation cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform and the treatment of Graft-Versus-Host Disease using its ex vivo expanded and enhanced stem cells.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact: Endonovo Therapeutics, Inc. Mr. Steven Barnes Vice President of Investor Relations (800) 701-1223, Ext. 108 Sbarnes@endonovo.com www.endonovo.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 137

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 21

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 184

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 319

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 114

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 191

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Crest Auto Group Teams Up with Football Star Kevin Jennings

Updated Category News Views 228

Crest Auto Group Partners with Rising Star Kevin Jennings Crest Auto Group, a renowned automotive dealership with a strong legacy in the industry, is taking a giant leap forward by announcing its inaugural collegiate Name, Image, and Likeness (NIL) partnership with the exceptional Kevin Jennings. As a team captain and quarterback, Jennings hails from a community that...

Continue Reading
Carolwood Estates Celebrates a Stellar 2024 Year of Growth

Updated Category News Views 390

Carolwood Estates Unveils Its 2024 Annual Report In a remarkable demonstration of resilience and success, Carolwood Estates has released its 2024 Annual Report, shining a spotlight on a fabulous year filled with record-breaking accomplishments. Under the leadership of CEO Drew Fenton, the brokerage has made notable strides within the competitive landscape of luxury real...

Continue Reading
Savage Appoints Josh Anders as Strategic Chief Financial Officer

Updated Category News Views 896

Welcoming Josh Anders to Savage Leadership Savage is thrilled to announce the appointment of Josh Anders as the new Chief Financial Officer (CFO) of the company. With a strong background in finance and a wealth of experience in various financial leadership roles, Anders is set to join the ranks of Savage’s effective global supply chain team. Experience and Leadership...

Continue Reading
John Hardin Enhances UBS Private Wealth Management Team in Miami

Updated Category News Views 91

UBS Welcomes New Financial Advisor in Miami UBS Private Wealth Management is making significant strides in enhancing its service offerings in South Florida with the inclusion of John Hardin as a Financial Advisor. This strategic move aims to bolster the firm's presence in Miami, strengthening relationships with clients and expanding the wealth management team. An...

Continue Reading
Investors Urged to Act by October: Hims & Hers Health Update

Updated Category News Views 270

Attention Hims & Hers Health Investors Investors holding shares in Hims & Hers Health, Inc. are urged to stay vigilant regarding significant developments affecting their investments. The Company, often simply referred to as Hims, is currently facing securities class action lawsuits filed by investors who believe they suffered financial losses during a specified period....

Continue Reading